NR3C2 and type 2 diabetes mellitus: The nonsteroidal mineralocorticoid receptor antagonist, finerenone, reducing kidney and cardiovascular fibrosis in experimental studies (Kolkhof et al., 2014; Grune et al., 2018), has recently been shown to reduce progression of kidney and cardiovascular complications in type 2 diabetes (Agarwal et al., 2022).